Skip to main content

Table 3 Baseline Characteristics of CHC, GT1 and IL28B-CC patients

From: CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV

Variables Overall NR (11)a non-NR (34)a P value
Age (years) 59.60 ± 8.62 60.00 ± 7.01 59.47 ± 9.17 0.862
Male (%) 60.0 63.6 58.8 0.725
BMI (Kg/m2) 25.24 ± 3.01 25.56 ± 3.39 25.14 ± 2.92 0.693
AST (U/L) 75.76 ± 35.93 85 ± 42 73 ± 34 0.313
ALT (U/L) 98.82 ± 55.79 104 ± 56 97 ± 56 0.741
HCV RNA (log10 IU/ml) 2.39(6.22)b 4.09(12.27)b 3.97(5.56)b 0.927
Diabetes Mellitus (%) 26.7 13.6 32.3 0.072
Liver cirrhosis (%) 24.4 45.5 17.6 0.039
  1. anumber of patients shown in parentheses
  2. bmedian (IQR) shown in parentheses
  3. Data are shown as mean ± standard deviation. Statistic analysis was done by Mann-Whitney test for comparison. Significant P values are shown in bold. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HCV, hepatitis C virus; IL28B, Interleukin-28B